Advertisement

Contraceptive safety among women with cystic fibrosis: a systematic review

      Abstract

      Background

      With dramatic improvements in life expectancy for cystic fibrosis (CF) patients, contraception for women with CF has become an important issue. There are theoretical concerns that hormonal contraceptive use among women with CF may impact disease severity or risk for other adverse health outcomes, including thrombosis and poor bone health, as well as concerns that malabsorption or altered drug metabolism might impact contraceptive effectiveness.

      Objective

      To evaluate evidence on the safety and effectiveness of contraceptive methods among women with CF.

      Search Strategy

      We searched the PubMed database for all articles published from database inception through October 2015.

      Selection Criteria

      We included studies that examined measures of disease severity, other health outcomes or indicators of contraceptive effectiveness among women with CF initiating or continuing a contraceptive method.

      Results

      Seven studies met our inclusion criteria. Three observational studies of fair to poor quality suggest that use of oral contraceptives (OCs) does not negatively impact CF disease severity, defined as changes in pulmonary function, number of exacerbations or need for intravenous antibiotics. Three small studies of poor quality reported on contraceptive failure among women with CF using combined hormonal contraceptives (combined OCs, patch or ring). One pregnancy was reported in a patch user out of 43 hormonal contraceptive users across all studies. One pharmacokinetic study reported that women with CF achieve steroid hormone plasma concentrations similar to healthy women after ingestion of combined OCs.

      Conclusions

      Limited evidence suggests that hormonal contraceptive use does not negatively impact disease severity among women with CF and that hormonal contraceptive effectiveness is not impaired by CF. Studies were limited by small sample sizes and short duration of follow-up. No studies examined the effect of hormonal contraception on thrombosis or bone health among women with CF.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Cystic Fibrosis Foundation Patient Registry annual data report, 2012.
        Cystic Fibrosis Foundation, Bethesda, MD2013
        • Sweezey NB
        • Ratjen F
        The cystic fibrosis gender gap: potential roles of estrogen.
        Pediatr Pulmonol. 2014; 49: 309-317
        • Quon BS
        • Aitken ML
        Cystic fibrosis: what to expect now in the early adult years.
        Paediatr Respir Rev. 2012; 13: 206-214
        • Roe AH
        • Traxler S
        • Schreiber CA
        Contraception in women with cystic fibrosis: a systematic review of the literature.
        Contraception. 2016; 93: 3-10
        • Centers for Disease Control and Prevention
        U.S. medical eligibility criteria for contraceptive use, 2010.
        MMWR Recomm Rep. 2010; 59: 1-86
        • Moher D
        • Liberati A
        • Tetzlaff J
        • Altman DG
        • Group P
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        BMJ. 2009; 339: b2535
        • Harris RP
        • Helfand M
        • Woolf SH
        • et al.
        Current methods of the US Preventive Services Task Force: a review of the process.
        Am J Prev Med. 2001; 20: 21-35
        • Kernan NG
        • Alton EW
        • Cullinan P
        • Griesenbach U
        • Bilton D
        Oral contraceptives do not appear to affect cystic fibrosis disease severity.
        Eur Respir J. 2013; 41: 67-73
        • Chotirmall SH
        • Smith SG
        • Gunaratnam C
        • Cosgrove S
        • Dimitrov BD
        • O'Neill SJ
        • et al.
        Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis.
        N Engl J Med. 2012; 366: 1978-1986
        • Fitzpatrick SB
        • Stokes DC
        • Rosenstein BJ
        • Terry P
        • Hubbard VS
        Use of oral contraceptives in women with cystic fibrosis.
        Chest. 1984; 86: 863-867
        • Stead RJ
        • Grimmer SF
        • Rogers SM
        • Back DJ
        • Orme ML
        • Hodson ME
        • et al.
        Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis.
        Thorax. 1987; 42: 59-64
        • Plant BJ
        • Goss CH
        • Tonelli MR
        • McDonald G
        • Black RA
        • Aitken ML
        Contraceptive practices in women with cystic fibrosis.
        J Cyst Fibros. 2008; 7: 412-414
        • Kissner DG
        Role of progestational agents in the treatment of undernourished patients with cystic fibrosis.
        Pediatr Pulmonol. 2000; 29: 244
        • Bader Y
        • Helmy S
        • Promberger R
        • Marschalek J
        • Jirecek S
        • Jaksch P
        • et al.
        Hormonal contraception in female lung transplant recipients: a case series.
        J Fam Plann Reprod Health Care. 2014; 40: 294-296
        • Spino M
        Pharmacokinetics of drugs in cystic fibrosis.
        Clin Rev Allergy. 1991; 9: 169-210
        • Moran A
        • Dunitz J
        • Nathan B
        • Saeed A
        • Holme B
        • Thomas W
        Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality.
        Diabetes Care. 2009; 32: 1626-1631
        • van den Berg JM
        • Morton AM
        • Kok SW
        • Pijl H
        • Conway SP
        • Heijerman HG
        Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD).
        J Cyst Fibros. 2008; 7: 515-519
        • Takemoto CM
        Venous thromboembolism in cystic fibrosis.
        Pediatr Pulmonol. 2012; 47: 105-112
        • Paccou J
        • Zeboulon N
        • Combescure C
        • Gossec L
        • Cortet B
        The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis.
        Calcif Tissue Int. 2010; 86: 1-7
        • Curtis KM
        • Martins SL
        Progestogen-only contraception and bone mineral density: a systematic review.
        Contraception. 2006; 73: 470-487
        • Aris RM
        • Merkel PA
        • Bachrach LK
        • Borowitz DS
        • Boyle MP
        • Elkin SL
        • et al.
        Guide to bone health and disease in cystic fibrosis.
        J Clin Endocrinol Metab. 2005; 90: 1888-1896
      2. Orkambi [package insert].
        Vertex Pharmaceuticals Incorporated, Boston, MA2016